IN2014MN02475A - - Google Patents

Info

Publication number
IN2014MN02475A
IN2014MN02475A IN2475MUN2014A IN2014MN02475A IN 2014MN02475 A IN2014MN02475 A IN 2014MN02475A IN 2475MUN2014 A IN2475MUN2014 A IN 2475MUN2014A IN 2014MN02475 A IN2014MN02475 A IN 2014MN02475A
Authority
IN
India
Application number
Inventor
Diego Dolcetta
Original Assignee
Diego Dolcetta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diego Dolcetta filed Critical Diego Dolcetta
Publication of IN2014MN02475A publication Critical patent/IN2014MN02475A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN2475MUN2014 2012-05-11 2014-12-05 IN2014MN02475A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000814A ITMI20120814A1 (en) 2012-05-11 2012-05-11 INTRATECAL, PREFERIBLY INTRAVENTRICULAR ADMINISTRATION OF MTOR INHIBITORS FOR THE THERAPY OF SOME NEURODEGENERATIVE, NEURO-INFLAMMATORY, NEURO-ONCOLOGICAL DISEASES
PCT/IB2013/053792 WO2013168131A1 (en) 2012-05-11 2013-05-10 Intrathecal administration of mtor inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncologic diseases

Publications (1)

Publication Number Publication Date
IN2014MN02475A true IN2014MN02475A (en) 2015-07-10

Family

ID=46582908

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2475MUN2014 IN2014MN02475A (en) 2012-05-11 2014-12-05

Country Status (10)

Country Link
US (2) US20150132397A1 (en)
EP (1) EP2846770B1 (en)
CN (1) CN104427975A (en)
DK (1) DK2846770T3 (en)
ES (1) ES2686561T3 (en)
IN (1) IN2014MN02475A (en)
IT (1) ITMI20120814A1 (en)
PL (1) PL2846770T3 (en)
PT (1) PT2846770T (en)
WO (1) WO2013168131A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104490873A (en) * 2014-11-25 2015-04-08 邹丽萍 Child tuberous sclerosis treatment drug
GB2564383B (en) * 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CN109187839A (en) * 2018-10-25 2019-01-11 美康生物科技股份有限公司 The kit and detection method of four kinds of immunosuppressant drug concentrations in Accurate Determining people's whole blood
CN109406650A (en) * 2018-10-25 2019-03-01 美康生物科技股份有限公司 Kit and detection method for four kinds of immunosuppressant drug concentrations in Accurate Determining people's whole blood
IT202000007228A1 (en) * 2020-04-06 2021-10-06 Diego Dolcetta ADMINISTRATION OF mTOR INHIBITORS IN THE CENTRAL NERVOUS SYSTEM
KR20230037647A (en) * 2020-07-14 2023-03-16 얀센 파마슈티카 엔.브이. Blood-based assay to detect tauopathies or amyloidosis
JP2023546504A (en) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ.ベー. How to reduce tau in human subjects

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502188A (en) * 2002-09-17 2006-01-19 ニューヨーク ユニバーシティ Methods for treating age-related memory deficits (AAMI), moderate cognitive deficits (MCI), and dementia with cell cycle inhibitors
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20090274764A1 (en) * 2008-04-30 2009-11-05 Do Hiep Q Hollow Foam Beads for Treatment of Glioblastoma
EP2456437A4 (en) * 2009-07-24 2013-01-09 Inst Nat Rech Scient Combinations of curcummoids and mtor inhibitors for the treatment of tauopathies

Also Published As

Publication number Publication date
DK2846770T3 (en) 2018-09-17
PL2846770T3 (en) 2019-02-28
CN104427975A (en) 2015-03-18
ES2686561T3 (en) 2018-10-18
ITMI20120814A1 (en) 2013-11-12
EP2846770A1 (en) 2015-03-18
EP2846770B1 (en) 2018-06-13
US20160324770A1 (en) 2016-11-10
US20150132397A1 (en) 2015-05-14
WO2013168131A1 (en) 2013-11-14
PT2846770T (en) 2018-10-15

Similar Documents

Publication Publication Date Title
BR112014018151A2 (en)
BR112014017614A2 (en)
BR112014018879A2 (en)
BR112014017592A2 (en)
BR112014017625A2 (en)
BR112014019285A2 (en)
AR092201A1 (en)
BR112014019496A2 (en)
BR112013027865A2 (en)
BR112014017634A2 (en)
BR112014017609A2 (en)
BR112014017588A2 (en)
BR112014017618A2 (en)
BR112014013184A8 (en)
BR112014017630A2 (en)
BR112014017621A2 (en)
BR112014017622A2 (en)
BR112014017627A2 (en)
BR112014017623A2 (en)
BR112014019350A2 (en)
BR112014017641A2 (en)
BR112014017631A2 (en)
IN2014MN02475A (en)
BR112014017671A2 (en)
BR112014017596A2 (en)